PPARγ: Welcoming the New Kid on the CML Stem Cell Block

Cancer Cell. 2015 Oct 12;28(4):409-411. doi: 10.1016/j.ccell.2015.09.017.

Abstract

Recently, chronic myeloid leukemia (CML) patients already responding to treatment showed improved molecular responses with pioglitazone, presumably through PPARγ activation and CML stem cell eradication. Given data demonstrating deepening responses and successful treatment discontinuation with current therapy, the necessity for new therapies targeting CML stem cells to achieve cure is unclear.

Publication types

  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides / administration & dosage*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Neoplastic Stem Cells / drug effects*
  • PPAR gamma / agonists*
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Thiazolidinediones / administration & dosage*

Substances

  • Benzamides
  • PPAR gamma
  • Piperazines
  • Pyrimidines
  • Thiazolidinediones